Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors

Core Insights - Connect Biopharma has expanded its Board of Directors from six to seven members with the appointment of Jim Schoeneck, who brings over 40 years of experience in drug development and commercialization [1][2][3] Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on transforming care for asthma and chronic obstructive pulmonary disease (COPD) [4] - The company is advancing rademikibart, a next-generation antibody targeting IL-4Rα, currently undergoing global clinical studies for treating acute exacerbations of asthma and COPD [4] Leadership and Expertise - Jim Schoeneck's appointment is expected to enhance the company's strategic and commercial capabilities, particularly in advancing the development and commercialization of rademikibart [2][3] - Schoeneck has held leadership positions in various biotech firms and has a strong background in guiding companies through significant transformations [3] Product Development - Rademikibart is positioned to address the needs of millions of patients with asthma or COPD who experience acute exacerbations annually [2] - The company anticipates clinical data from its Phase 2 Seabreeze STAT studies in the first half of 2026 [2]